| [1] |
Roupret M, Babjuk M, Comperat E, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma：2015 update[J]. Eur Urol, 2015, 68(5): 868-879．
|
| [2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| [3] |
廖洪，李汉忠，张玉石. 单中心尿路上皮癌2115例临床特点分析[J]. 中华泌尿外科杂志, 2014, 35(12): 900-904.
|
| [4] |
Seisen T, Granger B, Colin P, et al. A Systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma[J]. Eur Urol, 2015, 67(6): 1122-1133.
|
| [5] |
Xiong G, Yao L, Hong P, et al. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients[J]. Cancer Manag Res, 2018, 10(1): 6627-6639.
|
| [6] |
Takahashi T, Kakehi Y, Mitsumori K, et al. Distinct microsatellite alterationsin upper urinary tract tumors and subsequent bladder tumors[J]. J Urol, 2001, 165(2): 672-677.
|
| [7] |
Hafner C, Knuechel R, Stoehr R, et al. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies[J].Int J Cancer, 2002, 101(1): 1-6.
|
| [8] |
Yamashita S, Ito A, Mitsuzuka K, et al. Clinical implications of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma[J]. Int J Urol,2016, 23(5): 378-384.
|
| [9] |
Chung JH, Song W, Kang M, et al. Conditional intravesical recurrence-free survival rate after radical nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma[J]. Front Oncol, 2021, 11: 730114.
|
| [10] |
Zigeuner RE, Hutterer G, Chromecki T, et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location[J].BJU Int, 2006, 98(6): 1181-1186.
|
| [11] |
Narukawa T, Hara T, Arai E, et al. Tumour multifocality andgrade predict intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma without a history of bladder cancer[J]. Jpn J Clin Oncol, 2015, 45(5): 488-493.
|
| [12] |
袁贺佳，吴吉涛，门昌平，等. 后腹腔镜联合经尿道电切镜术后继发膀胱癌的危险因素分析[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2016, 10(4): 226-229.
|
| [13] |
Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: A systematic review and meta-analysis[J]. BJU Int, 2017, 120(3): 313-319.
|
| [14] |
Elalouf V, Xylinas E, Klap J, et al. Bladder recurrence after radical nephroureterectomy：predictors and impact on oncological outcomes[J]. Int J Urol, 2013, 20(11): 1078-1083.
|
| [15] |
Shigeta K, Kikuchi E, Hagiwara M, et al. Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma[J].Surg Oncol, 2017, 26(1): 73-79.
|
| [16] |
Ahmed M, Harraz, Magdy E, et al. Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a randomized clinical trial[J]. Clin Genitourin Cancer, 2019, 17(6): 1108-1115.
|
| [17] |
Yanagi M, Hamasaki T, Akatsuka J, et al. Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma[J]. BMC Urol, 2021, 21(1): 167.
|
| [18] |
Sakamoto N, Naito S, Kumazawa J, et al. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study[J].Int J Urol, 2001, 8(5): 212-216.
|
| [19] |
Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase ii trial of a single early intravesical instillation of pirarubicin (thp) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the thp monotherapy study group trial[J]. J Clin Oncol, 2013, 31(11): 1422-1427.
|
| [20] |
O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)[J]. Eur Urol, 2011, 60(4): 703-710.
|
| [21] |
Wu WJ, Ke HL, Yang YH, et al. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy[J].J Urol, 2010, 183(1): 56-61.
|
| [22] |
Yuan H, Mao X, Bai Y, et al. The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis[J]. J Chemother, 2015, 27(4): 195-200.
|
| [23] |
Dobé T, Califano G, von R, et al. Postoperative chemotherapy bladder instillation after radical nephroureterectomy: results of a european survey from the young academic urologist urothelial cancer group[J]. Eur Urol Open, 2020, 22(22): 45-50.
|
| [24] |
Michael A, Uhlman MA, Bing MT, et al. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy[J]. BMC Urol, 2015, 15(1): 45-51.
|
| [25] |
Nadler N, Oedorf K, Jensen J, et al. Intraoperative mitomycin c bladder installation during radical nephroureterectomy is feasible and safe[J]. Eur Urol Open Sci, 2021, 34(34): 41-46.
|
| [26] |
黄健，王建业，孔垂泽，等.中国泌尿外科和男科疾病诊断治疗指南[M]. 2019版. 北京: 科学出版社, 2019: 202.
|
| [27] |
Wu P, Zhu G, Wei D, et al. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis[J]. J BUON, 2015, 20(5): 1229-1238.
|
| [28] |
Yuval F, Rashed G, Nirmish S, et al. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy[J]. Urol Oncol, 2020, 38(9): 737.e11-737.e16.
|
| [29] |
Fan, B, Teng, Q, Sun, M, et al. Assessment of therapeutic benefit and option strategy on intravesical instillation for preventing bladder cancer recurrence after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma[J]. J Oncol, 2022, 1755368.
|
| [30] |
Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE)[J]. Bladder Cancer, 2016, 2(1): 27-36.
|
| [31] |
Long X, Qi L, Zu X, et al. Prevention of recurrent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinoma: an individualized selection strategy based onpatient risk stratification is needed[J]. Urol Int, 2017, 98(3): 312-319.
|
| [32] |
Huang Y, Cen J, Liu Z, et al. A comparison of different prophylactic intravesical chemotherapy regimens for bladder cancer recurrence after nephroureterectomy for primary upper tract urothelial carcinomas: a retrospective 2-center study[J].Technol Cancer Res Treat, 2019, 18(1): 1-9.
|
| [33] |
Miyake M, Tatsumi Y, Matsumoto H, et al. Outcomes of subsequent non-muscleinvasive bladder cancer treated with intravesical Bacillus Calmette‐Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma[J]. BJU Int, 2018, 121(5): 764-773.
|
| [34] |
Lu DD, Boorjian SA, Raman JD, et al. Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists[J]. Urol Oncol, 2017, 35(3): 113.e1-e7.
|
| [35] |
Metcalfe M, Wagenheim G, Xiao L, et al. Induction and maintenance adjuvant mitomycin c topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes[J]. J Endourol, 2017, 31(9): 946-953.
|
| [36] |
Yoo SH, Jeong CW, Kwak C, et al.Intravesical chemotherapy after radical nephroureterectomy for primary upper tract urothelial carcinoma:asystematic review and network meta-analysis[J]. J Clin Med, 2019, 8(7): 1059.
|
| [37] |
Miyamoto K, Ito A, Wakabayashi M, et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III)[J]. Jpn J Clin Oncol, 2018, 48(1): 94-97.
|
| [38] |
吴肖冰，葛力源，戴黎阳，等.上尿路尿路上皮癌术后预防性膀胱灌注化疗的临床意义[J]. 中华泌尿外科杂志, 2017, 38(4): 286-289.
|
| [39] |
王安莲，王勋，刘赟，等. 上尿路尿路上皮癌术后膀胱内复发的危险因素及预防性膀胱灌注化疗的意义[J]. 国际泌尿系统杂志, 2019, 39(3): 457-460.
|
| [40] |
Fechner G, Pocha K, Schmidt D, et al. Reducing recurrence and costsin superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin[J].Int J Clin Pract, 2006, 60(10): 1178-1180.
|
| [41] |
Satoshi Y, Shinichi S, Yusuke I, et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma[J].Int J Urol, 2019, 26(8): 791-796.
|
| [42] |
廖国栋，俞蔚文，张琦，等. 单次与多次膀胱灌注方案对原发性上尿路尿路上皮癌术后预后的影响[J]. 中国临床药理学与治疗学, 2017, 22(4): 461-465.
|